Safety/feasibility clinical study of TBX.CD NSCs conducted at City of Hope (COH) in patients with recurrent high-grade glioma completed in 2013
TBX capitalizes on discovery by founder, Dr. Aboody, and others that:
- NSCs have a natural ability to home to and penetrate invasive tumor sites
- NSCs can be modified to deliver a variety of anti-cancer agents
- NSCs can cross the blood brain barrier
- Note that 98% of current chemotherapeutic agents cannot reach the brain.
First-in-human clinical studies for recurrent high grade glioma patients
Figure Legend: TBX NSCs are engineered to stably express an enzyme (cytosine deaminase; CD) that can convert an inactive prodrug (5-flurocytosine; 5-FC) to an active chemotherapeutic agent (5-Flurouracil; 5-FU). During tumor resection or biopsy, TBX.CD NSCs are administered to the patient, and localize to residual tumor sites. Three days later, the prodrug 5-FC is given orally for a week. 5-FC crosses the blood brain barrier and gets activated to 5-FU by the TBX.CD NSCs. TBX NSCs provide tumor-localized chemotherapy production, sparing normal tissues from toxic side effects, potentially reducing suffering and improving quality of life.